comparemela.com

Latest Breaking News On - Nicola scharrer - Page 1 : comparemela.com

The International Centers for Precision Oncology: ICPO Foundation presents its first Maurits W Geerlings Actinium-225 Next Generation Award to Dr Madhav Yadav from AIIMS, India at the 6th Theranostics World Congress (TWC)

ICPO Foundation presents its first Maurits W Geerlings Actinium-225 Next Generation Award to Dr Madhav Yadav from AIIMS, India at the 6th Theranostics World Congress (TWC)

ICPO Foundation presents its first Maurits W Geerlings Actinium-225 Next Generation Award to Dr Madhav Yadav from AIIMS, India at the 6th Theranostics World Congress (TWC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Petrichor Managing Partner Tadd Wessel Joins the ICPO Foundation Board of Curators

WIESBADEN, Germany, May 25, 2022 / B3C newswire / The International Centers for Precision Oncology (ICPO) Foundation is pleased to announce new support from Petrichor Healthcare Capital Management (Petrichor) and the appointment of Tadd Wessel, Petrichor’s Founder and Managing Partner, to the ICPO Board of Curato.

ITM Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline

ITM AG: ITM to Host Virtual Symposium on New Approaches for Targeted Radionuclide Therapy in Precision Oncology with Key Opinion Leaders on Friday, June 4th, 2021 in Parallel to 2021 ASCO Annual Meeting

(0) ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual symposium titled, New Approaches for Targeted Radionuclide Therapy in Precision Oncology as an ancillary event in parallel to the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The symposium will feature renowned key opinion leaders in the field and will be held on Friday, June 4 th, 2021 from 9.30 am 11.00 am ET 3.30 pm 5.00 pm CEST. The interactive live-session will explore the latest science and clinical practices driving Targeted Radionuclide Therapy to the forefront of the precision oncology field. Participating experts will lead critical examinations and discussions surrounding topics including the current and future potential of Targeted Radionuclide Therapy in cancer therapy and diagnostics, its application in hard-to-treat indications such as gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) and novel developments in the field, including ITM s pro

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.